Chronic stable angina pharmacotherapy to prevent MI and death in asymptomatic patients

Editors-In-Chief: C. Michael Gibson, M.S., M.D. [mailto:mgibson@perfuse.org] Phone:617-632-7753; ; Associate Editors-In-Chief: John Fani Srour, M.D.; Jinhui Wu, MD.

==ACC / AHA Guidelines- Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients (DO NOT EDIT) == {{cquote|

Class I
1. Aspirin in the absence of contraindication in patients with prior MI. (Level of Evidence: A)

2. Beta-blockers as initial therapy in the absence of contraindications in patients with prior MI. (Level of Evidence: B)

3. Lipid-lowering therapy in patients with documented CAD and LDL cholesterol greater than 130 mg/dL, with a target LDL of less than 100 mg/dL. (Level of Evidence: A)

4. ACE inhibitor in patients with CAD who also have diabetes and/or left ventricular systolic dysfunction. (Level of Evidence: A)

Class IIa
1. Aspirin in the absence of contraindications in patients without prior MI. (Level of Evidence: B)

2. Beta-blockers as initial therapy in the absence of contraindications in patients without prior MI. (Level of Evidence: C)

3. Lipid-lowering therapy in patients with documented CAD and LDL cholesterol 100 to 129 mg/dL, with a target LDL of 100 mg/dL. (Level of Evidence: C)

4. ACE inhibitor in all patients with CAD or other vascular disease. (Level of Evidence: B)}}

Guidelines Resources

 * Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology


 * The ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina


 * The ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina


 * The 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina